Clinical perspectives on medical marijuana (cannabis) for neurologic disorders

Neurology: Clinical Practice

Volumn 5, Issue 4, 2015, Pages 344-351

  Fife, Terry D ^a,b   Moawad, Heidi ^c   Moschonas, Constantine ^d   Shepard, Katie ^e   Hammond, Nancy ^f  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c JOHN CARROLL UNIVERSITY   (United States)

^d Four Peaks Neurology   (United States)

^e AMERICAN ACADEMY OF NEUROLOGY   (United States)

^f UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DRONABINOL; MEDICAL CANNABIS; NABILONE; NABIXIMOLS;

ANOREXIA; ARTICLE; CANCER PAIN; CANNABIS USE; CENTRAL NERVOUS SYSTEM; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; EXPIRATORY RESERVE VOLUME; HUMAN; INSURANCE; LONG TERM CARE; LONG TERM MEMORY; MUSCLE ATROPHY; NEUROLOGIC DISEASE; NONHUMAN; PATIENT COUNSELING; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW (TOPIC);

EID: 84939559414     PISSN: 21630402     EISSN: 21630933     Source Type: Journal    
DOI: 10.1212/CPJ.0000000000000162     Document Type: Article

References (26)

1. Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014; 82: 1556-1563
2. Macdonald S, Hall W, Roman P, Stockwell T, Coghlan M, Nesvaag S. Testing for cannabis in the work-place: a review of the evidence. Addiction 2010; 105: 408-416
3. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006; 5: 993-996
4. Lovinger DM. Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol 2008; 184: 435-477
5. Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem 1993; 61: 352-355
6. Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005; 168: 1-51
7. Caballero A, Tseng KY. Association of cannabis use during adolescence, prefrontal CB1 receptor signaling, and schizophrenia. Front Pharmacol 2012; 3: 101
8. Devinsky O, Sullivan J, Friedman D, et al. Epidiolex (Cannabidiol) in treatment resistant epilepsy [press release]. American Academy of Neurology April 13, 2015. Available at: https://www.aan.com/PressRoom/Home/GetDigitalAsset/11570. Accessed June 15, 2015
9. Greydanus DE, Hawver EK, Greydanus MM, Merrick J. Marijuana: current concepts. Front Public Health 2013; 1: 42
10. Marinol (Dronabinol). Available at: http://www.fda.gov/ohrms/dockets/dockets/05n0479/05N-0479-emc0004-04.pdf. Updated September 2004. Accessed March 3, 2015
11. Hoffmann DE, Weber E. Medical marijuana and the law. N Engl J Med 2010; 362: 1453-1457
12. Bostwick JM. Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc 2012; 87: 172-186
13. American College of Physicians. Supporting Research into the Therapeutic Role of Marijuana. Philadelphia: American College of Physicians; 2008. Position Paper. (Available at American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106).
14. Kassirer JP. Federal foolishness and marijuana. N Engl J Med 1997; 336: 366-367
15. Adler JN, Colbert JA. Clinical decisions. Medicinal use of marijuana-polling results. N Engl J Med 2013; 368: e30
16. American Academy of Neurology. Position Statement: Use of Medical Marijuana for Neurologic Disorders. Published 2014. Available at: https://www.aan.com/uploadedFiles/Website-Library-Assets/Documents/6.Public-Policy/1.Stay-Informed/2.Position-Statements/3.PDFs-of-all-Position-Statements/Final%20Medical%20Marijuana%20Position%20Statement.pdf. Accessed February 27, 2015
17. DuPont RL. Getting Tough on Gateway Drugs: A Guide for the Family. Washington, DC: American Psychiatric Press; 1984
18. Polich JM, Ellickson PL, Reuter P, Kahan JP. Strategies for Controlling Adolescent Drug Use. Santa Monica, CA: Rand Corporation; 1984
19. Hall WD, Lynskey M. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev 2005; 24: 39-48
20. Rocchetti M, Crescini A, Borgwardt S, et al. Is cannabis neurotoxic for the healthy brain? A metaanalytical review of structural brain alterations in non-psychotic users. Psychiatry Clin Neurosci 2013; 67: 483-492
21. Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 2011; 5: 1-8
22. Indelekofer F, Plechatzek M, Daamen M, et al. Reduced memory and attention performance in a population-based sample of young adults with a moderate life-time use of cannabis, ecstasy and alcohol. J Psychopharmacol 2009; 23: 495-509
23. Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA 2012; 307: 173-181
24. Pavisian B, MacIntosh BJ, Szilagyi G, Staines RW, OConnor P, Feinstein A. Effects of cannabis on cognition in patients with MS: a psychometric and MRI study. Neurology 2014; 82: 1879-1887
25. GW Pharmaceuticals Initiates Second Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome [press release]. London, UK: GW Pharmaceuticals; 2015. Available at: http://www.gwpharm.com/GW%20Pharmaceuticals%20Initiates%20Second%20Phase%203%20Pivotal%20Trial%20for%20Epidiolex %20in%20Dravet%20Syndrome.aspx?. Accessed April 27, 2015
26. Conant v McCaffrey, U.S. District Court, Northern District of California, No. C 97-00139 WHA, September 7, 2000. Available at: https://www.wamm.org/conant-v-mccaffrey.pdf. Accessed April 26, 2015